Showing results (71-80 of 259) with videos related to
Sort By:
Pageof 26
Clinical Lung Cancer|January 27, 2016
First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III TrialMark Boye, Xin Wang, Vichien Srimuninnimit, et al.JTO Clinical and Research Reports|September 30, 2021
Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With <i>Kras</i> Mutation in East Asian Populations: A Single-Center Cohort Study in TaiwanShang-Gin Wu, Wei-Yu Liao, Kang-Yi Su, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|August 16, 2024
Real-world analysis of survival outcomes in advanced EGFR-mutant NSCLC patients treated with platinum-pemetrexed after EGFR-TKI treatment failureZong-Han Yao, Wei-Yu Liao, Chin-Yao Yang, et al.Lung Cancer (Amsterdam, Netherlands)|April 27, 2012
Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancerMyung-Ju Ahn, James Chih-Hsin Yang, Jun Liang, et al.JTO Clinical and Research Reports|September 30, 2021
Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC TrialJames Chih-Hsin Yang, Tony S K Mok, Shun Lu, et al.Oncology|January 25, 2012
Survival of patients with small cell lung carcinoma in TaiwanYu-Hsuan Kuo, Zhong-Zhe Lin, Yen-Yun Yang, et al.Clinical Lung Cancer|May 30, 2016
Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung CancerShun Lu, Ying Cheng, Cai-Cun Zhou, et al.Targeted Oncology|January 18, 2023
Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic StrategiesSanjay Popat, Myung-Ju Ahn, Simon Ekman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung CancerGeoffrey R Oxnard, Kenneth S Thress, Ryan S Alden, et al.Lung Cancer (Amsterdam, Netherlands)|March 1, 2021
Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysisPeey-Sei Kok, Kirsty Lee, Sally Lord, et al.Pageof 26